ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Exploration of shared gene signatures and molecular mechanisms between psoriasis and COVID-19: evidence from transcriptome data.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Emerging evidence suggests that the onset or worsening of psoriasis can occur following COVID-19 infection or vaccination. Additionally, individuals with psoriasis may be more susceptible to COVID-19. However, the underlying mechanisms driving this phenomenon remain unclear. This study aims to explore the potential shared mechanisms and the complex interplay between psoriasis and COVID-19. Gene expression profiles for COVID-19 (GSE162183) and psoriasis (GSE54456) were obtained from the Gene Expression Omnibus (GEO) database. Common differentially expressed genes (DEGs) were identified, followed by functional annotation, protein–protein interaction (PPI) network construction, and hub gene identification. Validation of hub genes was performed using independent datasets (GSE152075 and GSE157103 for COVID-19; GSE121212 and GSE78097 for psoriasis). Receiver operating characteristic (ROC) curves were used to assess the predictive value of the hub genes. Gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted, and expression patterns of the hub genes were further explored using a single-cell RNA sequencing dataset. A total of 66 common DEGs (all upregulated) were identified. The influenza A and NOD-like receptor signaling pathways were enriched in both COVID-19 and psoriasis. OAS2, MX1, IRF7, RSAD2, OASL, IFIT1, IFIT3, and ISG15 were identified as hub genes after validation, with all are under the curve (AUC) > 0.7 for COVID-19 and AUC > 0.9 for psoriasis. Upregulation of these hub genes was associated with increased infiltration of neutrophils and Th17 cells. Single-cell analysis showed that the hub genes were primarily expressed in epithelial cells in COVID-19 and keratinocytes in psoriasis. This study reveals shared pathogenic mechanisms between psoriasis and COVID-19 and provides insights into how COVID-19 may exacerbate psoriasis. The identified common pathways, hub genes, and associated cell types offer valuable guidance for future research and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.